Preventing diabetes complications

被引:3
|
作者
Templer, Sophie [1 ,2 ]
Abdo, Sarah [1 ,3 ]
Wong, Tang [1 ,2 ,3 ]
机构
[1] Bankstown Lidcombe Hosp, Dept Endocrinol, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW, Australia
关键词
diabetes; macrovascular complications; microvascular complications; cardiovascular disease; glycaemic control; INTENSIVE GLUCOSE CONTROL; CARDIOVASCULAR OUTCOMES; MICROVASCULAR OUTCOMES; INSULIN-TREATMENT; TYPE-2; MORTALITY; DISEASE; METAANALYSIS; MANAGEMENT; MELLITUS;
D O I
10.1111/imj.16455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The key aim of diabetes management is to prevent complications, which are a major cause of morbidity and mortality. At an individual level, people with diabetes are less likely than they were several decades ago to experience classical macrovascular and microvascular complications as a result of improvements in modifiable cardiovascular risk factors and preventive healthcare. However, a significant burden of diabetes complications persists at a population level because of the increasing incidence of diabetes, as well as longer lifetime exposure to diabetes because of younger diagnosis and increased life expectancy. Trials have shown that the most effective strategy for preventing complications of diabetes is a multifactorial approach focussing simultaneously on the management of diet, exercise, glucose levels, blood pressure and lipids. In addition to the cornerstone strategies of addressing diet, exercise and lifestyle measures, the introduction of newer glucose-lowering agents, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have brought about a paradigm shift in preventing the onset and progression of complications of type 2 diabetes, particularly cardiovascular and renal disease. The improvement in rates of classical complications of diabetes over time has been accompanied by a growing awareness of non-traditional complications, including non-alcoholic fatty liver disease. These emerging complications may not respond to a glycaemic-centred approach alone and highlight the importance of foundational strategies centred on lifestyle measures and supported by pharmaceutical therapy to achieve weight loss and reduce metabolic risk in patients living with diabetes.
引用
收藏
页码:1264 / 1274
页数:11
相关论文
共 50 条
  • [31] Renal complications of diabetes
    Min, T. Z.
    Stephens, M. W.
    Kumar, P.
    Chudleigh, R. A.
    BRITISH MEDICAL BULLETIN, 2012, 104 (01) : 113 - 127
  • [32] Severe Mental Illness and the Risk of Diabetes Complications: A Nationwide, Register-based Cohort Study
    Scheuer, Stine H.
    Kosjerina, Vanja
    Lindekilde, Nanna
    Pouwer, Frans
    Carstensen, Bendix
    Jorgensen, Marit E.
    Benros, Michael E.
    Andersen, Gregers S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (08) : E3504 - E3514
  • [33] Cardiovascular complications of diabetes
    Shah, Avisha
    Isath, Ameesh
    Aronow, Wilbert S.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (05) : 383 - 388
  • [34] Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
    Kruger, Davida F.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S43 - S52
  • [35] Process of Care Compliance Is Associated With Fewer Diabetes Complications
    Bayer, Felicia J.
    Galusha, Deron
    Slade, Martin
    Chu, Isabella M.
    Taiwo, Oyebode
    Cullen, Mark R.
    AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (01) : 41 - 52
  • [36] BIOMARKERS FOR DIABETES COMPLICATIONS: THE RESULTS OF SEVERAL CLINICAL STUDIES
    Aslan, Diler
    JOURNAL OF MEDICAL BIOCHEMISTRY, 2011, 30 (03) : 207 - 212
  • [37] Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?
    Ferguson, L. D.
    Sattar, N.
    DIABETES OBESITY & METABOLISM, 2013, 15 (05) : 387 - 391
  • [38] Pre-Existing Conditions Determining Current Diabetes Therapy: Mitigating Complications Involving the Heart and Kidneys
    Jaeckel, E.
    Schneider, C.
    Simon, J.
    Haller, H.
    DIABETES STOFFWECHSEL UND HERZ, 2019, 28 (06): : 339 - 348
  • [39] Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: Can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort
    Cardoso, Claudia R. L.
    Leite, Nathalie C.
    Salles, Gil F.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (02)
  • [40] Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes
    Kale, Ajinath
    Sankrityayan, Himanshu
    Anders, Hans-Joachim
    Gaikwad, Anil Bhanudas
    DRUG DISCOVERY TODAY, 2021, 26 (08) : 1963 - 1971